Skip to main content
OpenTrials
Completed

NCT Number: NCT04323683

The Effect of Progesterone on Human Endometrium

This study evaluates the relationship between progesterone levels and endometrial gene expression

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

Queen's medical center

Nottingham, NG7 2UH, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 18-35, regular menstrual cycles, the cycle length between 25 and 35 days, body mass index (BMI) between 18 - 25

Exclusion criteria

  • History of infertility, history of pelvic pain or/and endometriosis, history of pelvic mass, history of hormonal therapy in the last 3 months

Treatment and study plan

Microarray

Genetic

High throughput technique for determining global gene expression of the condition of interest

Primary outcomes

  1. Differentially expressed genes between women with low and normal progesterone

    Time frame: 2 months

    Fold-change and p-value were used to determine differentially expressed genes using Partek software

Sponsors and collaborators

Lead sponsor

University of Nottingham

Other

Registry information

Official study title

The Effect of Progesterone Levels on Human Endometrial Transcriptomics During the Implantation Window

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 26, 2020
Registry last updated
Mar 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.